School of Medicine
Showing 1-10 of 41 Results
-
Laura Michele Hack
Assistant Professor of Psychiatry and Behavioral Sciences (Public Mental Health and Population Sciences)
BioDr. Laura M. Hack is an Assistant of Psychiatry and Behavioral Sciences at Stanford University and the Veterans Affairs Palo Alto Health Care System (PAVAHCS). As Director of the Novel & Precision Neurotherapeutics Program at the Stanford Center for Precision Mental Health, Dr. Hack leads a translational, patient-centered research group that designs and implements mechanistic clinical trials for biologically informed subtypes of Mood, Anxiety, and Trauma-related Disorders (MATRDs).
Her work spans repurposed pharmacologic interventions (e.g., guanfacine), neuromodulation techniques (e.g., repetitive transcranial magnetic stimulation [TMS]), and therapies involving altered states of consciousness (i.e., ketamine, MDMA, psilocybin, and anesthesia-induced dreaming). Across these modalities, Dr. Hack's focus is on tailoring treatment based on objective, biologically anchored markers that match the patient’s profile.
Dr. Hack also directs the Stanford Translational Precision Mood Clinic (STeP-MC), a high-touch, high-tech consultation service designed to support individuals with a primary diagnosis of major depression and often comorbid MATRDs. This clinic integrates the investigational use of high-definition neuroimaging (personalized brain circuit scores) with symptom profiling, neurocognitive testing, pharmacogenomic analysis, inflammatory biomarkers, and standard blood work. The aim is to generate individualized insights that inform treatment decisions and help patients better understand the biological underpinnings of their condition—often reducing self-blame and empowering engagement in care.
In her role as Deputy Director as well as Ketamine and Education Lead of the Precision Neuromodulation Clinic (PNC) at PAVAHCS, Dr. Hack specializes in delivering evidence-based, FDA-cleared interventions including TMS and intranasal ketamine for Veterans experiencing treatment-resistant depression, frequently in the context of comorbid PTSD. -
Scott S. Hall, Ph.D
Professor of Psychiatry and Behavioral Sciences (Child and Adolescent Psychiatry and Child Development)
Current Research and Scholarly InterestsMy primary area of scholarly and clinical interest is the pathogenesis of problem behaviors shown by individuals diagnosed with intellectual and developmental disabilities (IDD), particularly those with neurogenetic forms of IDD, such as fragile X syndrome, Cornelia de Lange syndrome and Prader-Willi syndrome. My work aims to both advance understanding of these disorders and to identify effective new treatment approaches for pediatric and adult patient populations by state-of-the-art methodologies, such as brain imaging, eye tracking and functional analysis to determine how environmental and biological factors affect the development of aberrant behaviors in these syndromes. The end goal of my research is to create patient-specific methods for treating the symptoms of these disorders.
-
Joachim Hallmayer
Professor of Psychiatry and Behavioral Sciences (Child and Adolescent Psychiatry and Child Development)
On Partial Leave from 09/01/2024 To 08/31/2026Current Research and Scholarly InterestsPrincipal Investigator
Infrastructure to facilitate discovery of autism genes
The purpose of this project is to facilitate the discovery of the genes that contribute autism by maintaining an infrastructure which research groups studying the genetics of autism can work collaboratively. This will be
accomplished through workshops, a Virtual Private Network, and access to a database that includes phenotype and genotype data from all participating groups.
Principal Investigator
A California Population-Based Twin Study of Autism
This will address several fundamental questions: (1) What is the heritability of autism (2) What is the contribution of genetic factors to variation in symptom dimensions? (3) Is there a continuum between the quantitative neurocognitive traits and clinical disorder? (4) What proportion of the variance in the neurocognitive traits is accounted for by genetic and non-genetic factors?
Co-Investigator
Center for Integrating Ethics in Genetics Research(Cho)
The goal of this project is to serve as a center of excellence in neurogenetics research, to develop a national model for bench, to bedside research ethics consultation, and to provide training opportunity in biomedical ethics.
Co-Investigator
Gene, Brain and Behavior in Turner Syndrome(Reiss)
The primary objective of this project is to use advanced, multi-modal magnetic resonance imaging (MRI) techniques, analyses of X chromosome parent-of-origin and cognitive-behavioral assessment to elucidate the effects of monosomy and X-linked imprinting on neurodevelopment and neural function in a large cohort of young girls with Turner syndrome, pre-estrogen replacement.
Project Director
Project F: Genomic Analysis in narcolepsy cataplexy
The goal of the project is to locate genes outside the HLA region that influence susceptibility to narcolepsy. In order to localize these genes we will carry out a linkage and association study in the most extensive world-wide collection of DNAs from well-characterized patients with narcolepsy and their families. -
Bonnie Halpern-Felsher
Marron and Mary Elizabeth Kendrick Professor of Pediatrics and Professor, by courtesy, of Epidemiology and Population Health and of Psychiatry and Behavioral Sciences (Child and Adolescent Psychiatry)
Current Research and Scholarly InterestsResearch focuses on developmental, cognitive and psychosocial factors involved in adolescents’ and young adults’ health-related decision-making, perceptions of risk and vulnerability, health communication and risk behavior. My research has focused on understanding and reducing health risk behaviors such as tobacco use, alcohol and marijuana use, risky driving, and risky sexual behavior.
-
Antonio Hardan, M.D.
Professor of Psychiatry and Behavioral Sciences
On Partial Leave from 07/01/2025 To 08/31/2025Current Research and Scholarly InterestsThe neurobiology of autism
Neuroimaging in individuals with autism
Psychopharmacological treatment of children and adults with autism and/or developmental disorders
The neurobiology and innovative interventions of several neurogenic disorders including DiGeorge Syndrome (Velocardiofacial syndrome; 22q11.2 mutations), PTEN mutations, and Phelan McDermid Syndrome (22q13 mutations). -
Kate Hardy
Clinical Professor, Psychiatry and Behavioral Sciences
BioKate Hardy is a California Licensed Psychologist who has specialized in working with individuals with psychosis for over 20 years in both research and clinical settings. Dr. Hardy received her doctorate in clinical psychology from the University of Liverpool, United Kingdom. She has worked in specialist early psychosis services in both the UK and the US, including UCSF’s Prodrome Assessment Research and Treatment (PART) program, where she completed her post-doctoral fellowship, and as Clinical Director for the Prevention and Recovery from Early Psychosis (PREP) program. Dr. Hardy is the co-director for the INSPIRE clinic at the Department of Psychiatry and Behavioral Health, Stanford University and has significant experience in providing CBTp to individuals with early psychosis, and those at risk of developing psychosis, in both individual and group settings and integration of this clinical intervention to broader systems and staff teams. Dr. Hardy is also involved in the implementation of national strategies to increase dissemination of early psychosis models with the aim of bringing these cutting edge treatments to a broader population and is the co-editor of the book Intervening Early: A team approach.
Dr. Hardy is also the director of INSPIRE training and within this role has led multiple trainings and workshops in CBTp to a wide variety of audiences including community clinicians, psychiatrists, and families, and provides ongoing supervision and consultation in this approach. INSPIRE training offers training in evidence based interventions for psychosis to providers across diverse settings. In 2024 Dr. Hardy became president elect for IEPA: Intervening Early in Mental Health. -
Earth Hasassri, MD
Adjunct Clinical Assistant Professor, Psychiatry and Behavioral Sciences - Child & Adolescent Psychiatry and Child Development
BioDr. Earth Hasassri is an Adjunct Clinical Assistant Professor in the Department of Psychiatry and Behavioral Sciences, Division of Child and Adolescent Psychiatry and Child Development at Stanford University School of Medicine. He has a private practice in Menlo Park and teaches medical students, residents, and fellows at Stanford University School of Medicine. In his private practice, he specializes in seeing children and adults with complex psychiatric conditions such as ADHD, autism spectrum disorders, functional neurological disorders, those with epilepsy, and other neuropsychiatric conditions. His interests are caring for individuals who suffer from medical conditions at the interface of medicine and psychiatry.
Prior to medical school, Dr. Hasassri graduated with dual bachelor's degrees in neurophysiology and psychology at the University of California San Diego, where he performed research on sleep medicine. He earned his medical degree from the Mayo Clinic Alix School of Medicine where he did research in clinical epidemiology. Dr. Hasassri completed his residency in general psychiatry at the University of California San Francisco Langley Porter Psychiatric Hospitals & Clinics, during which he was awarded an Area of Distinction in Clinical Neuroscience for his work in applying neuroscientific principles in his clinical work in those with brain cancer, dementia, neurodevelopmental disorders, and other neuropsychiatric conditions. Dr. Hasassri is dual board certified in adult psychiatry and in child and adolescent psychiatry through the American Board of Psychiatry and Neurology, a member Board of the American Board of Medical Specialties.
